United States · Bill · HR
H.R. 6347 (114th)
To extend for one year the program for priority review to encourage treatments for rare pediatric diseases.
Introduced
17 November 2016
Last action
—
Status
Referred to the House Committee on Energy and Commerce.
Sponsors
—
Subjects
Discovery layer
Source updated
5 December 2025
Summary
This bill amends the Federal Food, Drug, and Cosmetic Act to extend through 2017 the priority review voucher program for treatments for rare pediatric diseases. (A priority review voucher is a transferable voucher that entitles the holder to have a new drug or biological product application acted upon by the Food and Drug Administration within six months.)
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 17 November 2016
Introduced in House (PDF)
Introduced in House · EN · 17 November 2016
Introduced in House
summary · EN · 17 November 2016
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/114th-congress/house-bill/6347
- Open data entity: https://api.congress.gov/v3/bill/114/hr/6347